Decera Clinical Education Medical Specialties Podcast

What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.Download the slides from this podcast at:https://bit.ly/3gpzuMjSee more NASH topics at:https://bit.ly/3ezkBq6

Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including:Should We Screen for NASH?Role of obesity and type 2 diabetes mellitusCardiovascular Risk in NAFLD/NASHHow to Evaluate for NAFLD/NASHBiomarkersImagingWhen/whom to biopsy?Management in Multidisciplinary SettingsDownload the slides from this podcast at:https://bit.ly/2ZBvVvySee more NASH topics at:https://bit.ly/3ezkBq6

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:• Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2• Assessment of therapeutic response• Assessment of long-term patient outcomesDownload the slides from this podcast at:https://bit.ly/3il5rqGSee more NASH topics at: https://bit.ly/3ezkBq6

Hear Philip N. Newsome, PhD, FRCPE, discussavailable approaches to managing NASH, including lifestyle, vitamin E, and compounds that target insulin resistance, including:Recommended Pharmacologic Therapies for NASHPioglitazoneVitamin EOptimal Diabetes Therapies in NAFLD/NASHWeight LossLiver HealthSurgical Approaches to Weight Loss and Effect on LiverDownload the slides from this podcast at:https://bit.ly/3ig0r6xSee more NASH topics at:https://bit.ly/3ezkBq6

Hear Dr. Katherine Wagner *and *Dr. Richard Finkle discussnovel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored.Download the slides from this podcast at: https://bit.ly/2zZgB2XSee more neurology topics at:https://bit.ly/3eAMVby

Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:Obeticholic acidCenicrivirocResmetiromAramcholDownload the slides from this podcast at:https://bit.ly/3eJYKvWSee more NASH topics at: https://bit.ly/3ezkBq6

Link to CME: Claim Credit - https://bit.ly/3dQPQwT .Continuous glucose monitoring (CGM) is a great tool that improves clinical outcomes for people with diabetes; these individuals are often happy to get this new technology.However, there can be some initial barriers that both people with diabetes and clinicians need to overcome.BARRIER 1: Wearing something on the body so other people know the person has diabetes.SOLUTION 1: Let the person see the size of different devices through demonstrations and